3. Umbruch 4.4..2005 - Online Pot

Cannabinoid targets for pain therapeutics 161
receptors. Anesthesiology 99: 955–960
53 Dray A (1995) Inflammatory mediators of pain. Br J Anaesth 75: 125–131
54 McMahon SB (1996) NGF as a mediator of inflammatory pain. Phil Trans R Soc Lond B Biol Sci
351: 431–440
55 Tracey DJ, Walker JS (1995) Pain due to nerve damage: are inflammatory mediators involved?
Inflamm Res 44: 407–411
56 Klegeris A, Bissonnette CJ, McGeer PL (2003) Reduction of human monocytic cell neurotoxicity
and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 139:
775–786
57 Rice AS, Farquhar-Smith WP, Nagy I (2002) Endocannabinoids and pain: spinal and peripheral
analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66:
243–256
58 Griffin G, Fernando SR, Ross RA, McKay NG, Ashford ML, Shire D, Huffman JW, Yu S, Lainton
JA, Pertwee RG (1997) Evidence for the presence of CB2-like cannabinoid receptors on peripheral
nerve terminals. Eur J Pharmacol 339: 53–61
59 Patel HJ, Birrell MA, Crispino N, Hele DJ, Venkatesan P, Barnes PJ, Yacoub MH, Belvisi MG
(2003) Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in
guinea-pigs by cannabinoid (CB2) receptor activation. Br J Pharmacol 140: 261–268
60 Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG, MacEwan DJ,
Scott RH (2001) Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications
for antinociception. Neuropharmacology 40: 221–232
61 Hohmann AG, Herkenham M (1999) Cannabinoid receptors undergo axonal flow in sensory
nerves. Neuroscience 92: 1171–1175
62 Price TJ, Helesic G, Parghi D, Hargreaves KM, Flores CM (2003) The neuronal distribution of
cannabinoid receptor type 1 in the trigeminal ganglion of the rat. Neuroscience 120: 155–162
63 Zeidenberg P, Clark WC, Jaffe J, Anderson SW, Chin S, Malitz S (1973) Effect of oral administration
of delta9 tetrahydrocannabinol on memory, speech, and perception of thermal stimulation:
results with four normal human volunteer subjects. Preliminary report. Compr Psychiatry 14:
549–556
64 Clark WC, Janal MN, Zeidenberg P, Nahas GG (1981) Effects of moderate and high doses of marihuana
on thermal pain: a sensory decision theory analysis. J Clin Pharmacol 21: 299S–310S
65 Raft D, Gregg J, Ghia J, Harris L (1977) Effects of intravenous tetrahydrocannabinol on experimental
and surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol
Ther 21: 26–33
66 Hill SY, Schwin R, Goodwin DW, Powell BJ (1974) Marihuana and pain. J Pharmacol Exp Ther
188: 415–418
67 Rukwied R, Watkinson A, McGlone F, Dvorak M (2003) Cannabinoid agonists attenuate capsaicin-induced
responses in human skin. Pain 102: 283–288
68 Arner S, Meyerson BA (1988) Lack of analgesic effect of opioids on neuropathic and idiopathic
forms of pain. Pain 33: 11–23
69 Noyes R Jr, Brunk SF, Avery DA, Canter AC (1975) The analgesic properties of delta-9-tetrahydrocannabinol
and codeine. Clin Pharmacol Ther 18: 84–89
70 Noyes R Jr, Brunk SF, Baram DA, Canter A (1975) Analgesic effect of delta-9-tetrahydrocannabinol.
J Clin Pharmacol 15: 139–143
71 Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL, Simone DA (2003) A
cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer
and inflammatory muscle pain. Pain 103: 175–186
72 Svendsen KB, Jensen TS, Bach FW (2004) Does the cannabinoid dronabinol reduce central pain
in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br Med J 329:
253
73 Herzberg U, Eliav E, Bennett GJ, Kopin IJ (1997) The analgesic effects of R(+)-WIN 55,212-2
mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett
221: 157–160
74 Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, James I (2001) The role of central
and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model
of neuropathic pain. Pain 92: 91–100
75 Bridges D, Ahmad K, Rice AS (2001) The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia
and allodynia in a rat model of neuropathic pain. Br J Pharmacol 133: 586–594